Literature DB >> 16138947

Sudden death in nondilated cardiomyopathies: pathophysiology and prevention.

Anand Soni1, Paul LeLorier.   

Abstract

Sudden cardiac death is a frequent cause of death and has been well studied in the setting of both ischemic and dilated cardiomyopathies. The primary and secondary prevention of sudden cardiac death has not been the focus of randomized clinical trials in the large cohort of patients with nondilated, nonischemic cardiomyopathies, however. Those disorders include hypertrophic cardiomyopathy and its apical variant, arrhythmogenic right ventricular cardiomyopathy, takotsubo cardiomyopathy, left ventricular noncompaction, cardiac amyloidosis, and cardiac sarcoidosis. In these conditions, risk stratification for sudden death is based on observational data.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16138947     DOI: 10.1007/s11897-005-0019-x

Source DB:  PubMed          Journal:  Curr Heart Fail Rep        ISSN: 1546-9530


  48 in total

1.  Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest : the Cardiac Arrest Study Hamburg (CASH).

Authors:  K H Kuck; R Cappato; J Siebels; R Rüppel
Journal:  Circulation       Date:  2000-08-15       Impact factor: 29.690

2.  Asymmetrical hypertrophy of the heart in young adults.

Authors:  D TEARE
Journal:  Br Heart J       Date:  1958-01

3.  Electrophysiologic abnormalities in AL (primary) amyloidosis with cardiac involvement.

Authors:  J Reisinger; S W Dubrey; M Lavalley; M Skinner; R H Falk
Journal:  J Am Coll Cardiol       Date:  1997-10       Impact factor: 24.094

4.  Primary systemic amyloidosis: clinical and laboratory features in 474 cases.

Authors:  R A Kyle; M A Gertz
Journal:  Semin Hematol       Date:  1995-01       Impact factor: 3.851

5.  A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias.

Authors: 
Journal:  N Engl J Med       Date:  1997-11-27       Impact factor: 91.245

6.  Canadian implantable defibrillator study (CIDS) : a randomized trial of the implantable cardioverter defibrillator against amiodarone.

Authors:  S J Connolly; M Gent; R S Roberts; P Dorian; D Roy; R S Sheldon; L B Mitchell; M S Green; G J Klein; B O'Brien
Journal:  Circulation       Date:  2000-03-21       Impact factor: 29.690

7.  Infusion of light chains from patients with cardiac amyloidosis causes diastolic dysfunction in isolated mouse hearts.

Authors:  R Liao; M Jain; P Teller; L H Connors; S Ngoy; M Skinner; R H Falk; C S Apstein
Journal:  Circulation       Date:  2001-10-02       Impact factor: 29.690

8.  Implantable cardioverter-defibrillator therapy for prevention of sudden death in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia.

Authors:  Domenico Corrado; Loira Leoni; Mark S Link; Paolo Della Bella; Fiorenzo Gaita; Antonio Curnis; Jorge Uriarte Salerno; Diran Igidbashian; Antonio Raviele; Marcello Disertori; Gabriele Zanotto; Roberto Verlato; Giuseppe Vergara; Pietro Delise; Pietro Turrini; Cristina Basso; Franco Naccarella; Francesco Maddalena; N A Mark Estes; Gianfranco Buja; Gaetano Thiene
Journal:  Circulation       Date:  2003-11-24       Impact factor: 29.690

9.  Arrhythmogenic right ventricular cardiomyopathy. Dysplasia, dystrophy, or myocarditis?

Authors:  C Basso; G Thiene; D Corrado; A Angelini; A Nava; M Valente
Journal:  Circulation       Date:  1996-09-01       Impact factor: 29.690

Review 10.  Arrhythmogenic right ventricular dysplasia/cardiomyopathy: need for an international registry. Study Group on Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy of the Working Groups on Myocardial and Pericardial Disease and Arrhythmias of the European Society of Cardiology and of the Scientific Council on Cardiomyopathies of the World Heart Federation.

Authors:  D Corrado; G Fontaine; F I Marcus; W J McKenna; A Nava; G Thiene; T Wichter
Journal:  Circulation       Date:  2000-03-21       Impact factor: 29.690

View more
  4 in total

Review 1.  Amyloidosis: pathogenesis and new therapeutic options.

Authors:  Giampaolo Merlini; David C Seldin; Morie A Gertz
Journal:  J Clin Oncol       Date:  2011-04-11       Impact factor: 44.544

Review 2.  Pathophysiology and treatment of systemic amyloidosis.

Authors:  Julian D Gillmore; Philip N Hawkins
Journal:  Nat Rev Nephrol       Date:  2013-08-27       Impact factor: 28.314

Review 3.  Takotsubo cardiomyopathy--a clinical review.

Authors:  Ana María Castillo Rivera; Manuel Ruiz-Bailén; Luis Rucabado Aguilar
Journal:  Med Sci Monit       Date:  2011-06

Review 4.  Primary noncompaction of the ventricular myocardium from the morphogenetic standpoint.

Authors:  U Bartram; J Bauer; D Schranz
Journal:  Pediatr Cardiol       Date:  2007-07-12       Impact factor: 1.838

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.